Niacin/lovastatin: Difference between revisions
Appearance
Content deleted Content added
Anypodetos (talk | contribs) m Copyedit |
m Moving Category:AbbVie brands to Category:Drugs developed by AbbVie per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands |
||
(28 intermediate revisions by 17 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Drug combination}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = |
||
⚫ | |||
| image |
| image = . |
||
| width = 100px |
|||
⚫ | |||
| image2 = Lovastatin2DCSD.svg |
|||
⚫ | |||
| width2 = 200px |
|||
| class1 = n/a |
|||
| component2 = Lovastatin |
|||
<!--Combo data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| class1 = [[Lipid-lowering agent]] |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
<!--Clinical data--> |
|||
⚫ | |||
| |
| = |
||
| |
| = <!-- / / / / / / --> |
||
⚫ | |||
⚫ | |||
| pregnancy_category = |
|||
⚫ | |||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
<!--Identifiers--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
⚫ | |||
| KEGG_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG = D10292 |
|||
<!--Chemical data--> |
|||
}} |
}} |
||
'''Niacin/lovastatin''' (trade names '''Advicor |
'''Niacin/lovastatin''' (trade names '''Advicor''') a drug combination used for the treatment of [[dyslipidemia]]. It a combination of [[niacin]] and the [[statin]] drug [[lovastatin]]. The combination preparation by [[Abbott Laboratories]] |
||
Advicor was approved by the U.S. Food and Drug Administration (FDA) on December 17, 2001.<ref>{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-249_Advicor.cfm |title=Advicor (Niacin Extended-Release & Lovastatin) Tablets |date= 13 September 2002 |website=U.S. Food and Drug Administration; Drug Approval Package|access-date=17 May 2020}}</ref> The FDA withdrew approval on 18 April 2016. The reason given: "Based on the collective evidence from several large cardiovascular outcome trials (Refs. 1-3.), the Agency has concluded that the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events." AbbVie Inc. agreed to voluntarily discontinue marketing Advicor.<ref name=FDAWithdrawal>{{cite web |url=https://www.federalregister.gov/documents/2016/04/18/2016-08894/abbvie-inc-withdrawal-of-approval-of-new-drug-applications-for-advicor-and-simcor |title=AbbVie Inc.; Withdrawal of Approval of New Drug Applications for ADVICOR and SIMCOR |date= 18 April 2016 |website=U.S. Federal Register|access-date=17 May 2020}}</ref> The same FDA action also applied to [[Niacin/simvastatin|Simcor]], a niacin-extended release combination with simvastatin.<ref name=FDAWithdrawal/> |
|||
It was approved by the FDA on December 17, 2001. |
|||
==Dosage== |
==Dosage== |
||
The combination |
The combination available as tablets containing : |
||
* 500 |
* 500mg/20mg |
||
* 750 |
* 750mg/20mg |
||
* 1000 |
* 1000mg/20mg |
||
* 1000 |
* 1000mg/40mg |
||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
==External links== |
|||
* [http://www.advicor.com Advicor] website |
|||
{{Statins}} |
{{Statins}} |
||
{{DEFAULTSORT:Niacin lovastatin}} |
|||
⚫ | |||
[[Category:Drugs developed by AbbVie]] |
|||
{{cardiovascular-drug-stub}} |
|||
[[Category:Hypolipidemic agents]] |
|||
⚫ |